| NCT ID | NCT05297331 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Urolithiasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2032-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-03-01 with a primary completion date of 2032-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an international prospective data registry to assess the treatment outcomes and complications of different treatment approaches for different surgical treatment of urolithiasis.
Eligibility Criteria
Inclusion Criteria: * Patient at the age of 18 or above Exclusion Criteria: * Patient is unable to give consent
Contact & Investigator
Chi Fai NG, MD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT05297331 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urolithiasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05297331 currently recruiting?
Yes, NCT05297331 is actively recruiting participants. Contact the research team at ngcf@surgery.cuhk.edu.hk for enrollment information.
Where is the NCT05297331 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Shatin, Hong Kong, Sheung Shui, Hong Kong.
Who is sponsoring the NCT05297331 clinical trial?
NCT05297331 is sponsored by Chinese University of Hong Kong. The principal investigator is Chi Fai NG, MD at Chinese University of Hong Kong. The trial plans to enroll 3,000 participants.